Dan 2014.

Methods	Study design: randomised clinical trial Study duration: January 2010 to January 2012 Duration of follow‐up: 2 years Setting: hospital
Participants	Inclusion criteria: diagnosed as HCC Age (mean ± SD, range): 58.5 ± 2.4 years, 25‐74 years Male (n/total): 85/120
Interventions	TACE + MWA group (n = 60): TACE: Chemotherapeutic drugs: 5‐fluorouracil 0.5‐1 g, cisplatin 40‐60 mg, and epirubicin 20‐40 mg MWA: the interval between TACE and MWA was 2 weeks. TACE group (n = 60): Chemotherapeutic drugs: 5‐fluorouracil 0.5‐1 g, cisplatin 40‐60 mg, and epirubicin 20‐40 mg
Outcomes	Tumour response: measured by image examinations 2‐year survival rate Adverse events
Notes	Country of study: China Source of funding: none There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.